Media formats available:
Recommended
- LDL-c: Done Deal, Next Epigenetics?A clinical view on BET inhibition in targeting residual risk in CVD and diabetes
Prof Kausik Ray
- LDL-c: Done Deal, Next Epigenetics?The real residual risk in patients with CVD & diabetes: The promise of epigenetics
Prof. Erik Stroes, MD